# Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

> **NCT02500043** · PHASE3 · COMPLETED · sponsor: **Taiho Oncology, Inc.** · enrollment: 507 (actual)

## Conditions studied

- Refractory Metastatic Gastric Cancer

## Interventions

- **DRUG:** TAS-102
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02500043
- **Lead sponsor:** Taiho Oncology, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-02-24
- **Primary completion:** 2018-04-30
- **Final completion:** 2019-12-19
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2024-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02500043

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02500043, "Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02500043. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*